Skip to main content

Advertisement

SpringerLink
Log in

Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

Abstract

This Practice point commentary discusses the findings of a randomized, multicenter, report published by Berthold et al, in which the results of the pivotal TAX 327 study are updated. The original TAX 327 study, published in 2004, randomly allocated men with castration-resistant prostate cancer to one of three chemotherapy regimens: docetaxel 75 mg/m2 administered every 3 weeks, docetaxel 30 mg/m2 administered weekly for 5 of every 6 weeks, or mitoxantrone 12 mg/m2 every 3 weeks. All patients received prednisone 5 mg twice daily. The original trial showed a significant survival benefit for those patients receiving docetaxel every 3 weeks compared with those receiving mitoxantrone. The updated analysis demonstrates that docetaxel remains the standard first-line chemotherapy for patients with castration-resistant prostate cancer. This commentary highlights the key results that were updated from the original TAX 327 study and also discusses several unresolved issues, including the optimum timing of chemotherapy initiation and its duration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. American Cancer Society. Cancer facts & figures 2007. [http://www.cancer.org/docroot/STT/stt_0_2007.asp?sitearea=STT&level=1] (accessed 23 April 2008)

  2. Food and Drug Administration (online 19 May 2004) FDA approves new indication for taxotere—prostate cancer. [http://www.fda.gov/bbs/topics/news/2004/NEW01068.html] (accessed 3 June 2008)

  3. Food and Drug Administration (online 13 November 1996) FDA approves new drug for treating prostate cancer. [http://www.fda.gov/bbs/topics/ANSWERS/ANS00771.html] (accessed 3 June 2008)

  4. Osoba D et al. (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17: 1654–1663

    Article  CAS  Google Scholar 

  5. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  CAS  Google Scholar 

  6. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  Google Scholar 

  7. Berthold DR et al. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242–245

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. B Schurko is a Clinical Research Coordinator for Genitourinary Oncology at Dana–Farber Cancer Institute, and WK Oh is an Associate Professor of Medicine at Harvard Medical School, and Clinical Director at the Lank Center for Genitourinary Oncology, Dana–Farber Cancer Institute, Boston, MA, USA.,

    Brian Schurko & William K Oh

Authors
  1. Brian Schurko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William K Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William K Oh.

Ethics declarations

Competing interests

B Schurko declared no competing interests. WK Oh receives grant/research support from Genentech and is a Consultant on the Speakers Bureau and receives grant/research support from Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schurko, B., Oh, W. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Rev Clin Oncol 5, 506–507 (2008). https://doi.org/10.1038/ncponc1201

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1201

  • Springer Nature Limited

This article is cited by

Search

Navigation